KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to -$830.0 million.

  • AbbVie's Net Cash Flow rose 8588.68% to -$830.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year increase of 7326.81%. This contributed to the annual value of -$7.2 billion for FY2024, which is 30024.94% down from last year.
  • Latest data reveals that AbbVie reported Net Cash Flow of -$830.0 million as of Q3 2025, which was up 8588.68% from $1.3 billion recorded in Q2 2025.
  • AbbVie's 5-year Net Cash Flow high stood at $5.3 billion for Q1 2024, and its period low was -$5.9 billion during Q3 2024.
  • For the 5-year period, AbbVie's Net Cash Flow averaged around -$138.5 million, with its median value being -$496.0 million (2023).
  • As far as peak fluctuations go, AbbVie's Net Cash Flow crashed by 55263.16% in 2021, and later soared by 31100.88% in 2024.
  • AbbVie's Net Cash Flow (Quarter) stood at -$2.4 billion in 2021, then fell by 10.22% to -$2.7 billion in 2022, then surged by 81.31% to -$496.0 million in 2023, then plummeted by 240.12% to -$1.7 billion in 2024, then surged by 50.8% to -$830.0 million in 2025.
  • Its last three reported values are -$830.0 million in Q3 2025, $1.3 billion for Q2 2025, and -$358.0 million during Q1 2025.